150 related articles for article (PubMed ID: 21547571)
21. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Chen YM; Perng RP; Lin WC; Wu HW; Tsai CM; Whang-Peng J
Am J Clin Oncol; 2002 Oct; 25(5):509-12. PubMed ID: 12393994
[TBL] [Abstract][Full Text] [Related]
22. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
[TBL] [Abstract][Full Text] [Related]
23. A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Grossi F; de Marinis F; Gebbia V; Riccardi F; Caffo O; Gamucci T; Ferraù F; Nardi M; Moscetti L; Boni L; Dondi D; Galligioni E
Cancer Chemother Pharmacol; 2012 Feb; 69(2):369-75. PubMed ID: 21833588
[TBL] [Abstract][Full Text] [Related]
24. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Yardley DA; Peacock NW; Dickson NR; White MB; Vázquez ER; Foust JT; Grapski R; Hendricks LK; Scott WL; Hainsworth JD
Clin Breast Cancer; 2010 Jun; 10(3):217-23. PubMed ID: 20497920
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Meyer F; Lueck A; Hribaschek A; Lippert H; Ridwelski K
Chemotherapy; 2004 Dec; 50(6):289-96. PubMed ID: 15608445
[TBL] [Abstract][Full Text] [Related]
26. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
[TBL] [Abstract][Full Text] [Related]
27. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
Yu Y; Xu X; Du Z; Shi M
Cancer Chemother Pharmacol; 2012 May; 69(5):1265-75. PubMed ID: 22297708
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Nielsen DL; Bjerre KD; Jakobsen EH; Cold S; Stenbygaard L; Sørensen PG; Kamby C; Møller S; Jørgensen CL; Andersson M
J Clin Oncol; 2011 Dec; 29(36):4748-54. PubMed ID: 22084374
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
De Castro J; Lorenzo A; Morales S; Belón J; Dorta J; Lizón J; Madroñal C; Gallurt PM; Casado E; Feliu J; Barón MG;
Cancer Chemother Pharmacol; 2005 Feb; 55(2):197-202. PubMed ID: 15322824
[TBL] [Abstract][Full Text] [Related]
30. A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
Matsui K; Hirashima T; Nitta T; Kobayashi M; Ogata Y; Furukawa M; Kudoh S; Yoshimura N; Mukohara T; Yamauchi S; Shiraishi S; Kamoi H; Negoro S; Takeda K; Nakagawa K; Takada M; Yana T; Fukuoka M
Jpn J Clin Oncol; 2005 Apr; 35(4):181-7. PubMed ID: 15845566
[TBL] [Abstract][Full Text] [Related]
31. Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.
Metro G; Fabi A; Russillo M; Papaldo P; De Laurentiis M; Ferretti G; Pellegrini D; Nuzzo C; Graziano V; Vici P; Introna M; Felici A; Cognetti F; Carlini P
Anticancer Res; 2008; 28(2B):1245-58. PubMed ID: 18505062
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
Giannatempo P; Pond GR; Sonpavde G; Raggi D; Naik G; Galsky MD; Bellmunt J; Necchi A
Eur Urol; 2016 Apr; 69(4):624-633. PubMed ID: 26497923
[TBL] [Abstract][Full Text] [Related]
33. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Frasci G; Comella P; D'Aiuto G; Thomas R; Capasso I; Elmo M; Botti G; Cortino GR; Lapenta L; De Rosa V; Vallone P; Petrillo A; Comella G
Ann Oncol; 2000 Mar; 11(3):367-71. PubMed ID: 10811508
[TBL] [Abstract][Full Text] [Related]
34. Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer.
Manegold C; Koschel G; Hruska D; Scott-von-Römer K; Mezger J; Pilz LR
Clin Lung Cancer; 2007 Jan; 8(4):245-51. PubMed ID: 17311688
[TBL] [Abstract][Full Text] [Related]
35. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Maniadakis N; Fragoulakis V; Pallis A; Prezerakos P; Georgoulias V
Lung Cancer; 2007 Nov; 58(2):275-81. PubMed ID: 17688969
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
Georgoulias V; Androulakis N; Kotsakis A; Hatzidaki D; Syrigos K; Polyzos A; Agelidou A; Varthalitis I; Ziras N; Agelidou M; Chandrinos V; Boukovinas I; Geroyianni A; Vamvakas L; Mavroudis D
Lung Cancer; 2008 Jan; 59(1):57-63. PubMed ID: 17765354
[TBL] [Abstract][Full Text] [Related]
37. Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study.
Syrigos KN; Karapanagiotou E; Charpidou A; Dilana K; Dannos I; Dionellis G; Rigopoulou A; Georgatou N; Roussos C
J Chemother; 2007 Aug; 19(4):438-43. PubMed ID: 17855189
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Dimopoulos AM; Kosmidis P; Papakostas P; Pavlidis N; Bacoyiannis C; Kiamouris C; Klouvas G; Gogas H; Fountzilas G; Samantas E;
Lung Cancer; 2003 Jul; 41(1):107-11. PubMed ID: 12826319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
